3284-52-4

Basic information

• Product Name: ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate
• Synonyms: ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate
• CAS NO: 3284-52-4
• Molecular Formula: C₁₅H₂₁NO₅S
• Molecular Weight: 327.399
• Mol File: 3284-52-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 463.358 °C at 760 mmHg
• Flash Point: 234.031 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.566
• CAS DataBase Reference: ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate(3284-52-4)
• EPA Substance Registry System: ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate(3284-52-4)

Safety Data

• Hazardous Substances Data: 3284-52-4(Hazardous Substances Data)

Usage

General Description

Ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate is a chemical compound with a complex name that describes its molecular structure. It is a tosylpyrrolidine derivative with an ethyl ester group and a hydroxy-methyl carboxylate group attached to a 3-methyl-1 position on the pyrrolidine ring. ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate is a synthetic intermediate that can be used in the production of various pharmaceuticals, agrochemicals, and other organic compounds. It is often used in organic synthesis as a building block for creating more complex molecules. The compound's specific properties and potential applications in chemistry and medicine may vary depending on its exact structure and purity.

InChI:InChI=1/C15H21NO5S/c1-4-21-14(17)13-15(3,18)9-10-16(13)22(19,20)12-7-5-11(2)6-8-12/h5-8,13,18H,4,9-10H2,1-3H3

Upstream product

• 3299-38-5 4-(diethylamino)butan-2-one 
• 5465-67-8 ethyl N-tosylglycinate 
• 98-59-9 p-toluenesulfonyl chloride 
• 1629-58-9 4-penten-3-one 
• 1080-44-0 N-Tosylglycine 
• 78-94-4 methyl vinyl ketone 

Downstream Products

• 3284-53-5 3-methyl-1-p-toluenesulfonyl-2,5-dihydro-1H-pyrrole-2-carboxylic acid ethyl ester 
• 1361938-29-5 C₁₅H₁₅NO₃ 
• 112381-11-0 ethyl 4-benzoyl-3-methylpyrrole-2-carboxylate 
• 1361938-30-8 C₁₆H₁₇NO₃ 
• 1361938-32-0 C₁₄H₁₃NO₃ 
• 90724-57-5 3-methyl-1H-pyrrole-2-carboxylic acid 
• 1188476-68-7 ethyl 3-methyl-1-tosyl-4,5-dihydro-1H-pyrrole-2-carboxylate 
• 3284-47-7 ethyl 3-methyl-1H-pyrrole-2-carboxylate 

Relevant articles and documents

Synthesis process method of 3-substituted-1H-pyrrole

The invention provides a synthetic process method of a 3-substituted-1H-pyrrole compound. The process method comprises the following steps: by taking diethylamine hydrochloride and glycine ethyl esterhydrochloride as initial raw materials, respectively carrying out Mannich reaction and sulfamide reaction, and carrying out cyclization reaction, dehydration thinning reaction, aromatization reactionand hydrolysis decarboxylation reaction to obtain a 3-substituted-1H-pyrrole compound. According to the synthesis process method of the 3-substituted-1H-pyrrole compound, the whole synthesis route isgood in step repeatability, mild in operation condition and high in safety, and large-scale production and industrial popularization are facilitated; post-treatment energy consumption is low, a largeamount of toxic wastewater is not generated, no pollution is caused to the environment, the production safety level and the production cost are reduced, application of green and environment-friendlyindustrial production is facilitated, and wide application prospects are achieved.

HETEROCYCLIC INHIBITORS OF NECROPTOSIS

The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induce

Pyrrole and pyrazole DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula I.